RxDoctor Payments DataLook up a doctor →

Karina Vila Rivera

Rheumatology · Barceloneta, PRNPI 1497952584

Payments from drug & device makers

$4,998,816in general payments, 2019–2025

Across 1,025 payments — averaging $4876.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3M
  • Eli Lilly Export S.A. Puerto Rico Branch$1.2M
  • Janssen Research & Development, LLC$452K
  • Sanofi US Services Inc.$260K
  • Takeda Pharmaceuticals U.S.A., Inc.$100K
  • Eli Lilly$28K
  • plus $9K from 17 others
$19,596in research payments, 2019–2025

Across 35 payments — averaging $559.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$14K
  • AbbVie$3K
  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$5,25336%
  • Travel & lodging$1,75512%
  • Food & beverage$7,31351%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,998,816 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab164$1,459,644
RinvoqUpadacitinib157$1,018,378
Enbrel SureclickEtanercept80$588,671
Xeljanz XrTofacitinib Citrate97$560,473
Orencia ClickjectAbatacept82$466,546
Humira PenAdalimumab22$264,100
BenlystaBelimumab54$258,740
OtezlaApremilast26$129,047
OrenciaAbatacept22$125,247
ProliaDenosumab54$95,341
EnbrelEtanercept11$83,540
TrulicityDulaglutide78$77,275
MounjaroTirzepatide52$56,336
RybelsusSemaglutide56$54,597
OzempicSemaglutide36$36,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella, Synthroid$2,992,101$1,036,397287 claims
AmgenOtezla, Prolia, Enbrel$2,201$307,92791 claims
GSKBenlysta$359$258,74054 claims
E.r. Squibb & Sons, L.L.C.Orencia$333$125,24722 claims
Novo NordiskRybelsus, Ozempic$515$91,34792 claims
Boehringer IngelheimJardiance$24$14,01319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Barceloneta

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →